Literature DB >> 8493989

Antiphospholipid antibodies in sickle cell disease.

O Kucuk1, A Gilman-Sachs, K Beaman, L J Lis, M P Westerman.   

Abstract

Antiphospholipid antibody formation can be induced in mice by phospholipid in a hexagonal II phase but not by phospholipid in a bilayer phase. Since sickle red cell membranes have increased hexagonal II phase content, we have measured serum antiphospholipid antibody levels in 25 patients with sickle cell disease to determine whether anti-phospholipid antibody may similarly be induced in these patients. Seventeen of the 25 patients (68%) had increased levels of antiphospholipid antibodies. Eleven patients (65%) had IgG and six each (35%) had IgM and IgA isotypes. Antiphosphatidylethanolamine, antiphosphatidylserine, antiphosphatidylinositol, and antiphosphatidic acid were the most frequently increased antibodies. The finding of increased antiphospholipid antibodies in these patients is compatible with the concept that antiphospholipid antibody formation is associated with structural changes in the red cell membrane and that such structural changes occur in the red cells of patients with sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8493989     DOI: 10.1002/ajh.2830420409

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

2.  Characterization and statistical modeling of glycosylation changes in sickle cell disease.

Authors:  Heather E Ashwood; Christopher Ashwood; Anna P Schmidt; Rebekah L Gundry; Karin M Hoffmeister; Waseem Q Anani
Journal:  Blood Adv       Date:  2021-03-09

Review 3.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

4.  Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus.

Authors:  L Casciola-Rosen; A Rosen; M Petri; M Schlissel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

Review 5.  Chronic Pulmonary Complications of Sickle Cell Disease.

Authors:  Alem Mehari; Elizabeth S Klings
Journal:  Chest       Date:  2016-01-13       Impact factor: 9.410

6.  The role of hypercoagulability in the development of osteonecrosis of the femoral head.

Authors:  Marios G Lykissas; Ioannis D Gelalis; Ioannis P Kostas-Agnantis; Georgios Vozonelos; Anastasios V Korompilias
Journal:  Orthop Rev (Pavia)       Date:  2012-05-29

7.  Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.

Authors:  A Parker Ruhl; S Christy Sadreameli; Julian L Allen; Debra P Bennett; Andrew D Campbell; Thomas D Coates; Dapa A Diallo; Joshua J Field; Elizabeth K Fiorino; Mark T Gladwin; Jeffrey A Glassberg; Victor R Gordeuk; Leroy M Graham; Anne Greenough; Jo Howard; Gregory J Kato; Jennifer Knight-Madden; Benjamin T Kopp; Anastassios C Koumbourlis; Sophie M Lanzkron; Robert I Liem; Roberto F Machado; Alem Mehari; Claudia R Morris; Folasade O Ogunlesi; Carol L Rosen; Kim Smith-Whitley; Danna Tauber; Nancy Terry; Swee Lay Thein; Elliott Vichinsky; Nargues A Weir; Robyn T Cohen; Elizabeth S Klings
Journal:  Ann Am Thorac Soc       Date:  2019-09

8.  Antiphospholipid Antibodies in Sickle Cell Disease: A Systematic Review and Exploratory Meta-Analysis.

Authors:  Mira Merashli; Alessia Arcaro; Maria Graf; Matilde Caruso; Paul R J Ames; Fabrizio Gentile
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.